Search Results

You are looking at 41 - 50 of 73 items for :

  • "zoledronic acid" x
Clear All
Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar

complications, improve performance status, and, importantly, preserve quality of life in patients with Durie-Salmon stage III MM and at least one lytic lesion. 189 , 190 Zoledronic acid has equivalent benefits. 191 Results from the study conducted by Zervas et

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

radiation therapy to boney sites. Early studies of pamidronate to prevent skeletal-related events confirmed its value in decreasing those events without direct impact on breast cancer or overall survival. 24 Subsequently, zoledronic acid and the monoclonal

Full access

James L. Mohler

skeletal-related events (zoledronic acid and denosumab). 18 Finally, men who develop castration-recurrent prostate cancer have new opportunities for therapy that extend beyond secondary ADT. Sipuleucel-T was shown to extend life expectancy in men with

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead and Rashmi Kumar

Similarly, zoledronic acid seems to have a different effect in patients with high versus low estrogen environments (postmenopausal vs premenopausal patients). In the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) trial, for patients

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer and Antonio C. Wolff

advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group . J Clin Oncol 1999 ; 17 : 846 – 854 . 214 Berenson JR Rosen LS Howell A . Zoledronic acid reduces skeletal

Full access

Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes and Vered Stearns

Schippinger WL . Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12 [abstract

Full access

James L. Mohler

. James ND Sydes MR Clarke NW . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial . Lancet

Full access

James L. Mohler

. 8. James ND Sydes MR Clarke NW . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Full access

Somasundaram Subramaniam, Jason A. Zell and Pamela L. Kunz

temozolomide in hopes of achieving tumor regression. He also received zoledronic acid for prophylaxis of skeletal events. He developed back pain, for which he had radiation therapy and vertebroplasty to the T12 vertebral body. He had stable disease through 7

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff and Richard Zellars

breast cancer in bone to prevent bone fractures, bone pain requiring radiation therapy, spinal cord compression, and hypercalcemia (skeletal related events [SREs]). 279 – 281 The bisphosphonates zoledronic acid or pamidronate have been used for this